Meeting
2023 ASCO Annual Meeting
Impact of EML4-ALK fusion variant and co-occurring TP53 mutation on treatment duration of first-line next-generation ALK TKIs in ALK fusion+ NSCLC.
Authors
Kaushal Parikh
Mayo Clinic, Rochester, MN
Kaushal Parikh , Anastasios Dimou , Konstantinos Leventakos , Yin Wan , Huamao Mark Lin , Sylvie Vincent , Jennifer Elliott , Ioana R Bonta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9029)
DOI
10.1200/JCO.2023.41.16_suppl.9029
Abstract #
9029
Poster Bd #
17
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.
First Author: Minsuk Kwon
Poster
2021 ASCO Annual Meeting
Circulating tumor DNA to investigate resistance mechanism and clone evolution of ALK TKI treated lung adenocarcinoma.
First Author: Gang Hua
Poster
2020 ASCO Virtual Scientific Program
Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.
First Author: D. Ross Camidge
Poster
2022 ASCO Annual Meeting
Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.
First Author: Alessandra Bearz